PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Blue Shield of CaliforniaAll Plans · Coverage · Genetic Testing · CA · Genetics, CardiologyMedium impact

Genetic Testing for Marfan Syndrome, Thoracic Aortic Aneurysms and Dissections, and Related Disorders (2.04.129)

Effective date
May 1, 2026
Identified
Nov 1, 2025

Summary

Blue Shield of California covers individual genetic testing for Marfan syndrome, Ehlers-Danlos syndrome type IV, other thoracic aortic aneurysm and dissection syndromes, and related disorders when signs and symptoms of a connective tissue disorder are present but a definitive diagnosis cannot be made using established clinical diagnostic criteria. The genes covered for individual testing and focused panels are FBN1, MYH11, ACTA2, TGFBR1, TGFBR2 and COL3A1. Targeted familial variant testing in an asymptomatic individual may be considered medically necessary when a known pathogenic variant is present in the family, and genetic testing panels that are not limited to focused genetic testing are considered investigational.

Get alerts when payers change rules like this one

We check Blue Shield of California and other payers every day and email you when a change matches your specialty and state.

Get Blue Shield of California alertsPolicy Monitoring is free. No card required.

What to do

Action · 5 steps
01Already effective May 1, 2026: The billing team should confirm that each genetic test billed is either individual testing of the listed genes for a suspected connective tissue disorder that clinical criteria cannot diagnose, or targeted testing for a known pathogenic variant in the family.
02Panels that are not limited to focused genetic testing are considered investigational under this policy.
03Documentation for clinical review must include history and physical or consultation notes covering previous diagnostic testing and responses with duration, family history, the reason for the test, how the test result will impact clinical decision making, and the signs, symptoms or test results related to the reason for testing.
04For post-service review, also include the results or reports of the tests performed.
05The policy's coding table is a general reference only, and inclusion of a code does not imply member coverage or provider reimbursement.

Codes mentioned

814018140581408814108141181479

Original notice

Genetic Testing for Marfan Syndrome, Thoracic Aortic Aneurysms and Dissections, and Related Disorders (2.04.129)
blueshieldca.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account